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rats served as controls. Animals were tested in open field, cross maze,
elevated plus maze, hole board, and in several motor function-related
tests. The incidence of EPS was examined twice.
Results: APD treatment in general had a significant sedative-like effect
on motor activity. Furthermore, drug-treated animals exhibit an anxious-
like phenotype and a loss of fine motor movements. The first detected
increase in EPS in APD-treated animals disappeared over time. Risperi-
done had a more stimulating effect on grooming behaviour whereas
haloperidol had a stronger sedative-like effect.
Conclusions: We have shown that the effects of APDs are not limited to
EPS. Domains such as anxiety and motor activity are affected as well.
Differences in the behavioural profile of typical and atypical APDs are
not restricted to EPS. This study demonstrates the importance of using
a comprehensive behavioural phenotyping strategy.
Keywords: Biological Psychiatry, Neuropsychiatry
514
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Purpose: The aim of this study was to examine the association between
latitude and the incidence and prevalence of schizophrenia based on two
recently-published systematic reviews.
Methods: Studies with original data related to the incidence and
prevalence of schizophrenia (published 1965–2002) were identified by
searching electronic databases, reviewing citations and writing to au-
thors. Exact latitude values were used for cities, and geocentral values
for other sites. The analyses were based on 353 incidence rates (from
68 studies) and 258 prevalence estimates (from 94 studies). Based on
three equal latitude bands, we compared the frequency measures of
schizophrenia for persons, males and females when adjusted for within-
study variation.
Results: Prevalence estimates from sites in the high latitude band were
significantly higher compared to lower bands (low and medium) for
persons (p < 0.005), males (p < 0.02) and females (p < 0.003). Inci-
dence rates were positively associated with absolute latitude for males
(p < 0.04), but neither for females (p = 0.06) nor persons (p = 0.69).
Conclusions: The interpretation of ecological studies requires caution,
however the results of this study suggest that risk factors that have lati-
tude gradients warrant closer inspection in schizophrenia epidemiology.
Keywords: Epidemiology, Aetiology, Other
515
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Recent research has explored the potential clinical utility of cognitive
remediation strategies to improve facial emotion recognition in patients
with schizophrenia. Observed facial identity and facial emotion recogni-
tion deficits are commonly interpreted as a dysfunction in the neurocog-
nitive mechanisms that underlie face processing. The role of extraocular
muscle (EOM) proprioception is largely neglected in these accounts.
This study uses an EOM training task to determine whether propri-
oceptive retraining of eye movements delivered using visual scanpath
technology improves emotion perception by assisting schizophrenia pa-
tients to develop more adaptive face viewing strategies. Subjects will be
randomly assigned to one of three remediation groups (proprioception
retraining group, face perception retraining group and control group
[computerised information only]) for six, weekly 30 minute sessions
and will complete follow-ups at 1 and 6 months post treatment in order
to explore the potential sustainability of gains made as a consequence of
remediation training. It is predicted that EOM proprioceptive retraining
will produce greater improvements in affect recognition accuracy and
visual scanpath strategies to face stimuli, and that these gains will be
more stable over time, than either face perception retraining or infor-
mation provision alone. The theoretical underpinnings of this unique
line of enquiry will be described, as will the novel methodology and
stimulus proposed for this research. Potential clinical significance and
expected outcomes will also be discussed.
Keywords: Epidemiology, Aetiology, Other
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Oxidative stress has recently been implicated in many psychiatric ill-
nesses including schizophrenia. This oxidative stress, in particular de-
pletion of glutathione (GSH), the primary endogenous antioxidant in
the brain, may be related to altered dopaminergic transmission. In
schizophrenia, recent studies have demonstrated 52% lower levels of
GSH levels cerebrospinal fluid and imaging studies have confirmed
prefrontal cortical deficits of this peptide. In order to investigate the be-
havioural consequences of GSH modulation, a suitable animal model is
required. 2-cyclohexene-1-one (CHX) has been used previously to de-
plete glutathione in various animal models. The current study aimed to
produce a dose-response curve investigating the biochemical response
to CHX dosing in parallel with locomotor behaviour testing. The ob-
ject of the study was to induce a similar degree of brain glutathione
depletion in mice to that in schizophrenia, but still maintain a normal
behavioural response.
Method: Doses ranging from 0 to 150 mg/kg of CHX were administered
to a total of 81 male C57BL/6 mice (average weight 25.9 g). Total
glutathione levels were assessed using an enzymatic-recycling assay.
Spontaneous locomotor activity was assessed using video-tracking with
Ethovision (Noldus).
Results: GSH levels were highest in striatum, followed by liver and
lowest in cortex samples. CHX treatment caused significant depletion
of GSH levels in striatum at 90 (33% decrease), 120 (38% decrease)
and 150 mg/kg (65% decrease). The effect of CHX was significant in
frontal cortex at 60 mg/kg and higher doses (27–59% depletion). In
contrast, there was no effect of CHX in the liver. In addition, there were
no major effects on spontaneous locomotor activity.
Conclusion: CHX causes regionally specific GSH depletion in mouse
brain without a peripheral effect or behavioural side-effects. This makes
it a useful model for use in brain and behavioural studies, including the
role of GSH in schizophrenia.
Keywords: Biological Psychiatry, Neuropsychiatry
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DISRUPTIONS OF PREPULSE INHIBITION IN
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The sex steroid hormone, estrogen, has been proposed to be protective
against schizophrenia. This study examined the effects of estrogen treat-
ment on modulation of prepulse inhibition (PPI) by the serotonin-1A
(5-HT1A) receptor partial agonist, buspirone. PPI is a model of senso-
rimotor gating, which is deficient in schizophrenia and other mental
illnesses. Eleven healthy women were tested following four acute treat-
ment conditions: placebo, buspirone (Buspar; 5 mg), estradiol (Estro-
fem; 2 mg), and combined buspirone and estradiol. Electromyogram
activity was measured across three inter-stimulus intervals: 30, 60 and
120 msec. There was no significant effect of either drug treatment on
startle amplitude or habituation. At the 120 msec inter-stimulus inter-
val, buspirone caused a significant disruption of PPI, whereas there was
no significant disruption of PPI with combined estrogen and buspirone
treatment. In conclusion, estrogen treatment, administered in the ap-
propriate experimental conditions, prevented PPI deficits induced by
5-HT1A receptor activation and may therefore also play a protective
role in sensorimotor gating deficits in schizophrenia.
Keywords: Biological Psychiatry, Neuropsychiatry
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Purpose: To compare hospitalisations in patients with schizophre-
nia/schizoaffective disorder three months before and after commencing
treatment with long-acting risperidone.
Methods: Data on 1,728 German and Australian patients initi-
ated on long-acting risperidone were extracted from the electronic-
Schizophrenia Treatment Adherence Registry (e-STAR), a secure
web-based, international observational study of patients with
schizophrenia. Retrospective and prospective data collection includes
patient demographics, disease characteristics and hospitalisations. Data
were available for the first three months after treatment initiation.
Results: Mean age was 41.8 (SD 13.5) years, 58.6% were male, and
mean duration of illness upon commencing treatment with long-acting
risperidone was 10.4 (SD 9.5) years. The majority of patients had a
diagnosis of schizophrenia (78.4%) or schizoaffective (18.1%) disorder.
Three months before treatment with long-acting risperidone, the average
number of days hospitalised was 13.3 (SD 23.5). This fell to an average
of 8.5 (SD 21.2) days after treatment (p < 0.001). The total number
of days hospitalised declined from 22,962 to 14,689 (p < 0.001), a
decrease of 8,273 days over the 3 month period. The proportion of
patients hospitalised also declined from 36.5% to 24.3% (p < 0.001).
The re-hospitalisation rate was 10.4% (95%CI: 8.9; 11.8) during the
3 months and the time to first re-hospitalisation was 89.4 (SD 72.3) days.
There were 124 patients (7.2%) who discontinued treatment with long-
acting risperidone, but unless lost to follow-up (3.8%), will continue to
be followed in the study.
Conclusion: Patients commencing treatment with long-acting risperi-
done seem less likely to be hospitalised during the first 3 months of
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